COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

194 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-23

Study Completion Date

2021-08-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammatory processes have been identified as key mediators of ischemia/ reperfusion injury in ST-segment elevation myocardial infarction. They add additional damage to the myocardium and are associated with clinical adverse events (heart failure and cardiovascular death) and poor myocardial recovery. All the different anti-inflammatory approaches to reduce reperfusion injury have been disappointing.

Colchicine is a well-known substance with potent anti-inflammatory properties. In a recent pilot study performed in 151 acute STEMI patients treated with primary percutaneous coronary intervention(PPCI) Deftereos et al. showed a 50% reduction of infarct size (creatine kinase release) with a short course treatment of colchicine in comparison to placebo.

One mechanism to explain this effect could be the reduction of adverse left ventricular (LV) remodelling. LV remodelling is part of the healing process of myocardium after MI. It is defined as the end diastolic volume (EDV) increase in the first months after MI. Adverse LV remodelling is increased by inflammation and ultimately leads to heart failure.

Our main hypothesis is that colchicine with its anti-inflammatory properties significantly reduces the initiation of adverse LV remodelling, together with a significant reduction of infarct size and microvascular obstruction in comparison to placebo in acute STEMI patients referred for PPCI.

After inclusion and randomisation, patients will receive the first part of their experimental treatment: colchicine or placebo before PCI, then, the second part after PCI and during 5 days. They will be followed up during their hospitalization and until one year. In order to evaluate LV remodelling, two cardiac magnetic resonance studies will be performed during their participation: one during their hospitalization and a second at 3 months. At 1 year, adverse events will be collected by phone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Colchicine on Coronary Reperfusion in Patients With Acute Coronary Syndrome

NCT05472337

Acute Coronary Syndrome

RECRUITING PHASE2

Colchicine Cardiovascular Outcomes Trial (COLCOT)

NCT02551094

Coronary Artery Disease Myocardial Infarction

COMPLETED PHASE3

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

NCT03487445

Acute Myocardial Infarction

COMPLETED PHASE2

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719

Acute Myocardial Infarction

ENROLLING_BY_INVITATION PHASE3

Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus

NCT03415386

Acute Myocardial Infarction Left Ventricular Thrombus

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colchicine

The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.

Group Type EXPERIMENTAL

Colchicine group (experimental arm)

Intervention Type DRUG

In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.

Control arm

The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.

Group Type PLACEBO_COMPARATOR

Placebo group (control arm)

Intervention Type DRUG

In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine group (experimental arm)

In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.

Intervention Type DRUG

Placebo group (control arm)

In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients, aged over 18 and \<80 years,
* Presenting within 12 hours of chest pain onset,
* With ST segment elevation ≥ 0.2 mV in two contiguous leads or new onset of left bundle branch block,
* Referral for primary percutaneous coronary intervention (PPCI).
* Preliminary oral informed consent followed by signed informed consent as soon as possible
* With an initially occluded coronary artery (TIMI angiographic flow of the culprit coronary artery ≤1)

Exclusion Criteria

* Patients with any legal protection measure,
* Patients without any health coverage,
* Patients with loss of consciousness or confused
* Patients with a history of prior myocardial infarction
* Patients with cardiogenic shock as defined by a systolic blood pressure \<90 mmHg, despite 30 minutes of fluid challenge or requiring intravenous vasoactive agents (dobutamine, noradrenaline, adrenaline)
* Patient with severe liver or known renal dysfunction (known GFR≤30 ml/min)
* Patient with known history of severe drug intolerance to colchicine
* Female patients currently pregnant or women of childbearing age not using contraception (oral diagnosis)
* Patients with any obvious contraindication to magnetic resonance imaging (claustrophobia, pace maker, defibrillator….)
* Patients treated by macrolides or pristinamycin
* Chronic treatment with COLCHICINE (Mediterranean familial fever mainly)
* Patient with lactose intolerance
* Patient with swallowing disorders

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No